Literature DB >> 9488705

Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX).

N Arispe1, J Ma, K A Jacobson, H B Pollard.   

Abstract

8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX) are xanthine adenosine antagonists which activate chloride efflux from cells expressing either wild-type or mutant (DeltaF508) cystic fibrosis transmembrane conductance regulator (CFTR). These drugs are active in extremely low concentrations, suggesting their possible therapeutic uses in treating cystic fibrosis. However, knowledge of the mechanism of action of these compounds is lacking. We report here that the same low concentrations of both CPX and DAX which activate chloride currents from cells also generate a profound activation of CFTR channels incorporated into planar lipid bilayers. The process of activation involves a pronounced increase in the total conductive time of the incorporated CFTR channels. The mechanism involves an increase in the frequency and duration of channel opening events. Thus, activation by these drugs of chloride efflux in cells very likely involves direct interaction of the drugs with the CFTR protein. We anticipate that this new information will contribute fundamentally to the rational development of these and related compounds for cystic fibrosis therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488705     DOI: 10.1074/jbc.273.10.5727

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Novel pharmacologic therapies for cystic fibrosis.

Authors:  P L Zeitlin
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

2.  Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.

Authors:  M Srivastava; O Eidelman; H B Pollard
Journal:  Mol Med       Date:  1999-11       Impact factor: 6.354

Review 3.  Purinergic regulation of epithelial transport.

Authors:  R Elaine Bucheimer; Joel Linden
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

Review 4.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 5.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 6.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  CFTR pharmacology.

Authors:  Olga Zegarra-Moran; Luis J V Galietta
Journal:  Cell Mol Life Sci       Date:  2016-10-04       Impact factor: 9.261

8.  Update and Review: Cystic Fibrosis.

Authors:  T Brown; E L Schwind
Journal:  J Genet Couns       Date:  1999-06       Impact factor: 2.537

9.  Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion.

Authors:  Paul C Zamecnik; Malay K Raychowdhury; David R Tabatadze; Horacio F Cantiello
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

10.  Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells.

Authors:  Meera Srivastava; Ofer Eidelman; Jian Zhang; Cloud Paweletz; Hung Caohuy; QingFeng Yang; Kenneth A Jacobson; Eliahu Heldman; Wei Huang; Catherine Jozwik; Bette S Pollard; Harvey B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.